ヴェラサイト
Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.32 | $150M | $43M |
| 2026 Q1 | 0.36 | $139M | $32M |
| 2025 Q4 | 0.52 | $141M | $48M |
| 2025 Q3 | 0.24 | $132M | $42M |
| 2025 Q2 | -0.01 | $130M | $32M |
| 2025 Q1 | 0.09 | $114M | $4M |
| 2024 Q4 |
| 0.07 |
| $119M |
| $20M |
| 2024 Q3 | 0.20 | $116M | $28M |